On the Transformative Potential of Advanced Therapeutics in Rare Disease
The burgeoning field of cell and gene therapies collectively referred to as Advanced Therapeutics (ADVTX), is at last beginning to...
Contributors
-
Account Manager -
President, USA -
-
Publications Executive -
Consultant -
Consultant -
Senior Consultant -
SVP -
Master Practitioner: Patient Insights -
Publications Assistant -
EVP, Oncology Practice Head -
Chief Commercial Officer -
US CEO -
Senior Consultant -
Associate Editorial Director -
Sr. Research Analyst -
Principal -
Research Executive -
Account Director -
Consultant -
Vice President -
Head of MedErgy (CH-MedErgy) -
Project Manager -
Project Manager -
Managing Consultant -
Senior Consultant -
Project Director -
Executive Vice President, Strategic Collaborations -
Associate Consultant
Cello Health Archive
- May 2019 (7)
- April 2019 (11)
- March 2019 (5)
- February 2019 (12)
- January 2019 (1)
- October 2018 (2)
- August 2018 (5)
- July 2018 (7)
- June 2018 (5)
- May 2018 (5)
- April 2018 (6)
- March 2018 (9)
- February 2018 (11)
- January 2018 (4)
- December 2017 (8)
- November 2017 (21)
- October 2017 (35)
- September 2017 (18)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- May 2017 (2)
- April 2017 (2)
- March 2017 (1)
- February 2017 (2)
- January 2017 (1)
- December 2016 (1)
- October 2016 (1)
Will the new NHS app help to solve issues in Rare Disease?
Following a successful pilot of the NHS app in 34 registered GP practices, the government are now looking to implement this offering...
5 key challenges for Biotech surrounding smaller patient populations and targeted therapies in Biotech - Part 5 of 5
Over the last few weeks, we have reviewed some key challenges that, based on our interviews at various biotech congresses, appear to be...
5 key challenges for Biotech surrounding smaller patient populations and targeted therapies in Biotech - Part 4 of 5
Over the last few weeks, we have reviewed some key challenges that, based on our interviews at various biotech congresses, appear to be...
5 key challenges for Biotech surrounding smaller patient populations and targeted therapies in Biotech - Part 3 of 5
Over the last couple of weeks, we have focused on some key challenges that, based on our interviews at various biotech congresses, appear...
As a free user, you can follow Passle and like posts.
To repost this post to your own Passle blog, you will need to upgrade your account.
For plans and pricing, please contact our sales team at sales@passle.net